GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Staar Surgical Co (NAS:STAA) » Definitions » Debt-to-EBITDA

Staar Surgical Co (Staar Surgical Co) Debt-to-EBITDA : 0.77 (As of Dec. 2023)


View and export this data going back to 1983. Start your Free Trial

What is Staar Surgical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Staar Surgical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.4 Mil. Staar Surgical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $31.5 Mil. Staar Surgical Co's annualized EBITDA for the quarter that ended in Dec. 2023 was $46.5 Mil. Staar Surgical Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.77.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Staar Surgical Co's Debt-to-EBITDA or its related term are showing as below:

STAA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -22.55   Med: 0.6   Max: 1.1
Current: 1.08

During the past 13 years, the highest Debt-to-EBITDA Ratio of Staar Surgical Co was 1.10. The lowest was -22.55. And the median was 0.60.

STAA's Debt-to-EBITDA is ranked better than
52.68% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.24 vs STAA: 1.08

Staar Surgical Co Debt-to-EBITDA Historical Data

The historical data trend for Staar Surgical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staar Surgical Co Debt-to-EBITDA Chart

Staar Surgical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 1.10 0.87 0.64 1.08

Staar Surgical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.30 2.04 0.81 1.18 0.77

Competitive Comparison of Staar Surgical Co's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Staar Surgical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Staar Surgical Co's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Staar Surgical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Staar Surgical Co's Debt-to-EBITDA falls into.



Staar Surgical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Staar Surgical Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.367 + 31.467) / 33.221
=1.08

Staar Surgical Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.367 + 31.467) / 46.468
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Staar Surgical Co  (NAS:STAA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Staar Surgical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Staar Surgical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Staar Surgical Co (Staar Surgical Co) Business Description

Traded in Other Exchanges
Address
25651 Atlantic Ocean Drive, Lake Forest, CA, USA, 92630
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also make lenses which are used in surgery that treats cataracts. The company offers products are ICLs used in refractive surgery and IOLs used in cataract surgery. The company generated sales are from the ophthalmic surgical product segment.
Executives
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Elizabeth Yeu Lin director 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aimee S Weisner director ONE EDWARDS WAY, IRVINE CA 92614
Warren Foust officer: Chief Operating Officer 17 MAGNOLIA DRIVE, LADERA RANCH CA 92694
Magda Michna officer: Chief Clinical, Regulatory, C/O PRESBIA, 8845 IRVINE CENTER DRIVE, SUITE 100, IRVINE CA 92618
Keith Holliday officer: V.P., Research & Development 1911 WALKER AVENUE, MONROVIA CA 91016
Robert Studholme officer: Senior VP, Operations 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
James E Francese officer: VP, Global Marketing 1911 WALKER AVE, MONROVIA CA 91016
Caren L Mason director 2523 PARK RIDGE DRIVE, ESCONDIDO CA 92025
Samuel J Gesten officer: VP, General Counsel 1911 WALKER AVENUE, MONROVIA CA 91016
Patrick F. Williams officer: Chief Financial Officer C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Hans-martin Blickensdoerfer officer: VP, International Marketing 1911 WALKER AVENUE, MONROVIA CA 91016
Lou Silverman director
Graydon C. Hansen officer: Sr. VP, Global Operations 25651 ATLANTIC OCEAN DRIVE, LAKE FORST CA 92630
Jon K. Hayashida officer: VP, Global Clinical, Medical 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630